These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 30776415)
1. Inhibition of PRMT3 activity reduces hepatic steatosis without altering atherosclerosis susceptibility in apoE knockout mice. Hoekstra M; Nahon JE; de Jong LM; Kröner MJ; de Leeuw LR; Van Eck M Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1402-1409. PubMed ID: 30776415 [TBL] [Abstract][Full Text] [Related]
2. PRMT3 inhibitor SGC707 reduces triglyceride levels and induces pruritus in Western-type diet-fed LDL receptor knockout mice. de Jong LM; Zhang Z; den Hartog Y; Sijsenaar TJP; Martins Cardoso R; Manson ML; Hankemeier T; Lindenburg PW; Salvatori DCF; Van Eck M; Hoekstra M Sci Rep; 2022 Jan; 12(1):483. PubMed ID: 35013582 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of protein arginine methyltransferase 3 activity selectively impairs liver X receptor-driven transcription of hepatic lipogenic genes in vivo. Nahon JE; Groeneveldt C; Geerling JJ; van Eck M; Hoekstra M Br J Pharmacol; 2018 Aug; 175(15):3175-3183. PubMed ID: 29774529 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice. Chen Y; Duan Y; Yang X; Sun L; Liu M; Wang Q; Ma X; Zhang W; Li X; Hu W; Miao RQ; Xiang R; Hajjar DP; Han J Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):948-59. PubMed ID: 25810299 [TBL] [Abstract][Full Text] [Related]
5. Functional interplay between liver X receptor and AMP-activated protein kinase α inhibits atherosclerosis in apolipoprotein E-deficient mice - a new anti-atherogenic strategy. Ma C; Zhang W; Yang X; Liu Y; Liu L; Feng K; Zhang X; Yang S; Sun L; Yu M; Yang J; Li X; Hu W; Miao RQ; Zhu Y; Li L; Han J; Chen Y; Duan Y Br J Pharmacol; 2018 May; 175(9):1486-1503. PubMed ID: 29394501 [TBL] [Abstract][Full Text] [Related]
7. Heparanase inhibition attenuates atherosclerosis progression and liver steatosis in E Muhammad RS; Abu-Saleh N; Kinaneh S; Agbaria M; Sabo E; Grajeda-Iglesias C; Volkova N; Hamoud S Atherosclerosis; 2018 Sep; 276():155-162. PubMed ID: 30075439 [TBL] [Abstract][Full Text] [Related]
8. Urotensin II receptor knockout mice on an ApoE knockout background fed a high-fat diet exhibit an enhanced hyperlipidemic and atherosclerotic phenotype. Bousette N; D'Orleans-Juste P; Kiss RS; You Z; Genest J; Al-Ramli W; Qureshi ST; Gramolini A; Behm D; Ohlstein EH; Harrison SM; Douglas SA; Giaid A Circ Res; 2009 Sep; 105(7):686-95, 19 p following 695. PubMed ID: 19696412 [TBL] [Abstract][Full Text] [Related]
9. DBZ (Danshensu Bingpian Zhi), a Novel Natural Compound Derivative, Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice. Wang J; Xu P; Xie X; Li J; Zhang J; Wang J; Hong F; Li J; Zhang Y; Song Y; Zheng X; Zhai Y J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971954 [TBL] [Abstract][Full Text] [Related]
10. A novel small molecule liver X receptor transcriptional regulator, nagilactone B, suppresses atherosclerosis in apoE-deficient mice. Gui Y; Yao S; Yan H; Hu L; Yu C; Gao F; Xi C; Li H; Ye Y; Wang Y Cardiovasc Res; 2016 Oct; 112(1):502-14. PubMed ID: 27460841 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of Atherosclerosis and Liver Steatosis by Agmatine in Western Diet-Fed apoE-Knockout Mice Is Associated with Decrease in Hepatic De Novo Lipogenesis and Reduction in Plasma Triglyceride/High-Density Lipoprotein Cholesterol Ratio. Wiśniewska A; Stachowicz A; Kuś K; Ulatowska-Białas M; Totoń-Żurańska J; Kiepura A; Stachyra K; Suski M; Gajda M; Jawień J; Olszanecki R Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639029 [TBL] [Abstract][Full Text] [Related]
12. G004, a synthetic sulfonylurea compound, exerts anti-atherosclerosis effects by targeting SIRT1 in ApoE Qian L; Ma L; Wu G; Yu Q; Lin H; Ying Q; Wen D; Gao C Vascul Pharmacol; 2017 Feb; 89():49-57. PubMed ID: 28069546 [TBL] [Abstract][Full Text] [Related]
13. Mitochondrial aldehyde dehydrogenase activation by Alda-1 inhibits atherosclerosis and attenuates hepatic steatosis in apolipoprotein E-knockout mice. Stachowicz A; Olszanecki R; Suski M; Wiśniewska A; Totoń-Żurańska J; Madej J; Jawień J; Białas M; Okoń K; Gajda M; Głombik K; Basta-Kaim A; Korbut R J Am Heart Assoc; 2014 Nov; 3(6):e001329. PubMed ID: 25392542 [TBL] [Abstract][Full Text] [Related]
14. Hydrogen decreases athero-susceptibility in apolipoprotein B-containing lipoproteins and aorta of apolipoprotein E knockout mice. Song G; Tian H; Qin S; Sun X; Yao S; Zong C; Luo Y; Liu J; Yu Y; Sang H; Wang X Atherosclerosis; 2012 Mar; 221(1):55-65. PubMed ID: 22209213 [TBL] [Abstract][Full Text] [Related]
15. LXR Agonist T0901317's Hepatic Impact Overrules Its Atheroprotective Action in Macrophages, Driving Early Atherogenesis in Chow-Diet-Fed Male Apolipoprotein E Knockout Mice. Hoekstra M; de Jong LM; van der Geest R; de Leeuw LR; Krisnamurthi R; Geerling JJ; Van Eck M Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672446 [TBL] [Abstract][Full Text] [Related]
16. Diminazene Aceturate Stabilizes Atherosclerotic Plaque and Attenuates Hepatic Steatosis in apoE-Knockout Mice by Influencing Macrophages Polarization and Taurine Biosynthesis. Stachowicz A; Wiśniewska A; Kuś K; Białas M; Łomnicka M; Totoń-Żurańska J; Kiepura A; Stachyra K; Suski M; Bujak-Giżycka B; Jawień J; Olszanecki R Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070749 [TBL] [Abstract][Full Text] [Related]